RESTART.

Trial name or title	REstart or STop Antithrombotics Randomised Trial (RESTART)
Methods	Allocation: randomised Blinding: treatment is open‐label, but outcome assessors are blinded Duration: at least 6 months Design: parallel Setting: UK National Health Service (NHS) secondary care (inpatient and outpatient services in stroke, neurology and neurosurgery) and primary care Dates: May 2013 to May 2018 (recruitment), November 2018
Participants	Inclusion criteria: Patient age ≥ 18 years. Spontaneous primary or secondary ICH. Patient had taken antithrombotic drug(s) for the prevention of vaso‐occlusive disease before ICH onset. Randomisation > 24 hours after ICH onset. Patient and their doctor are uncertain about whether to start or avoid antiplatelet drugs. Patient is registered with a general practitioner (GP). Brain imaging that first diagnosed the ICH is available. Participant or representative consent. Exclusion criteria: ICH due to preceding trauma or haemorrhagic transformation of ischaemic stroke. Patient is taking an anticoagulant drug following ICH. Patient is pregnant, breastfeeding, or of childbearing age and not taking contraception. Patient is being treated or followed up in another CTIMP. Patient and carer unable to understand spoken or written English. Brain magnetic resonance imaging (MRI) sub‐study: MRI done after ICH but before randomisation. No claustrophobia. MRI not contraindicated
Interventions	Participants will be randomised to either 'start antiplatelet medication' (restricted to the use of 1 or more of aspirin, dipyridamole or clopidogrel at the investigator's discretion) or "avoid antiplatelet medication"
Outcomes	Primary outcome measure: recurrent symptomatic ICH Secondary outcome measures: possible recurrent ICH; symptomatic non‐fatal extracerebral haemorrhage, extracranial haemorrhage, and vaso‐occlusive events; death; modified Rankin Scale score; adherence to antiplatelet drug(s)
Starting date	April 2013
Contact information	UK Chief Investigator: Rustam Al‐Shahi Salman; Trial Manager: Karen Innes RESTART.trial@ed.ac.uk.
Notes